Why Capricor Is Moving Markets Today — Full Breakdown

Capricor is among the top stories in the United States today. We reviewed 6 reports from FirstWord Pharma, Investing.com and 4 other publications to explain what happened, why it matters and what to watch next.
At a glance
- Published
- Nov 21, 2026 · 7:08 AM UTC
- Region
- United States
- Media coverage
- 6 outlets
- Main source
- FirstWord Pharma
- Category
- Finance & Markets
The Key Facts About Capricor
The biggest story this week came from FirstWord Pharma: “Capricor's DMD therapy hit by FDA rejection and trial integrity concerns”. Recurring themes in the coverage: therapy, duchenne, trial, shares.
Stories like this tend to matter because they can directly affect household budgets, borrowing costs, retirement accounts and portfolio performance.
Key Takeaways From Leading News Outlets

We analyzed 6 articles from FirstWord Pharma, Investing.com, Endpoints News, KFGO, STAT and Reuters. The earliest was published on November 20 at 11:42 PM UTC and the most recent on November 21 at 7:08 AM UTC.
Capricor's DMD therapy hit by FDA rejection and trial integrity concerns
Capricor shares plunge 80% as FDA cites trial violations in drug rejection
Capricor’s Duchenne therapy is rejected again, as FDA cites significant issues with trial
US FDA declines to approve Capricor’s cell therapy for Duchenne muscular dystrophy; shares slump
FDA rejects Capricor Therapeutics' Duchenne therapy, a decision that was a long time coming
Capricor's Duchenne treatment fails to get FDA approval, shares sink

Context: What You Need to Know First
Reference material on Capricor is being updated, but current coverage confirms several core facts:
- Capricor's DMD therapy hit by FDA rejection and trial integrity concerns (FirstWord Pharma)
- Capricor shares plunge 80% as FDA cites trial violations in drug rejection (Investing.com)
- Capricor’s Duchenne therapy is rejected again, as FDA cites significant issues with trial (Endpoints News)
What to Watch Next

- Any impact on consumer interest rates, loan costs or savings yields
- Analyst revisions and updated forecasts from large banks
- Official statements from regulators, central banks or company management
- How major indexes and related stocks react in the next trading sessions
Capricor remains an evolving story. Based on current reporting from FirstWord Pharma, Investing.com and others, the main facts are now clear, but details may change. Bookmark this page for updates.
Frequently Asked Questions
What happened with Capricor?
Key reports so far: Capricor's DMD therapy hit by FDA rejection and trial integrity concerns (FirstWord Pharma). Capricor shares plunge 80% as FDA cites trial violations in drug rejection (Investing.com). Capricor’s Duchenne therapy is rejected again, as FDA cites significant issues with trial (Endpoints News).
Which news outlets are reporting on Capricor?
At least 6 news organizations are covering the story, including FirstWord Pharma, Investing.com, Endpoints News, KFGO, STAT and Reuters. The most recent report in our review was published by FirstWord Pharma on November 21, 2026.
What are the key facts about Capricor?
Based on current reporting: Capricor's DMD therapy hit by FDA rejection and trial integrity concerns. Capricor shares plunge 80% as FDA cites trial violations in drug rejection. Capricor’s Duchenne therapy is rejected again, as FDA cites significant issues with trial.
This article is for informational purposes only and does not constitute financial advice. Always verify details with official sources or a licensed professional.
Quick poll
Will Capricor affect your personal finances?
Sources
- FirstWord Pharma — Capricor's DMD therapy hit by FDA rejection and trial integrity concerns
- Investing.com — Capricor shares plunge 80% as FDA cites trial violations in drug rejection
- Endpoints News — Capricor’s Duchenne therapy is rejected again, as FDA cites significant issues with trial
- KFGO — US FDA declines to approve Capricor’s cell therapy for Duchenne muscular dystrophy; shares slump
- STAT — FDA rejects Capricor Therapeutics' Duchenne therapy, a decision that was a long time coming
- Reuters — Capricor's Duchenne treatment fails to get FDA approval, shares sink
Nvidia Stock Market: What It Means for Your Money and the Markets








Discussion
No comments yet — start the discussion.